Augmentation of cisplatin with thymoquinone to target chemoresistant ovarian cancer in vitro study

Abstract

Background: Ovarian cancer (OvCa) is the leading gynecological cancer and has newlinebeen reported to have multi-drug resistance. Due to poor prognosis, women have low newlinesurvival rates and therapies have negative impacts on the quality of life. Resistance to newlineconventional treatments such as chemotherapy and radiation therapy is the reason for newlinethe need for innovative therapies. Phytochemicals (PCs) have demonstrated newlinesignificant potential in the field of OvCa by inhibiting metastasis of cancer cells. newlineThymoquinone (TQ) is a promising drug in the field of OvCa for inhibiting the cell newlineproliferation of cancer cells. newlineObjectives: The study demonstrates cisplatin (CDDP)- induced chemoresistance in newlineOvCa using in-vitro assays. The study also determines the anti-chemoresistance newlinemechanisms of CDDP along with TQ in OvCa. newline